A
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Anvesh Kompelli's research focuses on analyzing patient outcomes and treatment strategies, particularly within head and neck oncology and vascular malformations. His work frequently utilizes retrospective studies and database analyses to evaluate treatment efficacy, complications, and functional outcomes. Publications include investigations into the use of bleomycin for vascular malformations, functional outcomes after free flap surgery in older adults, and comparisons of radiotherapy versus surgery for laryngeal verrucous carcinoma. Kompelli has also explored neuroendocrine carcinomas of the oropharynx, readmission trends for infantile hemangioma treated with propranolol, and the feasibility of outpatient supraglottoplasty. His scholarship metrics include an h-index of 10 with 32 publications and 664 citations. Key collaborators at the University of Arkansas for Medical Sciences include Gresham T. Richter, James Reed Gardner, and Kyle P. Davis, with whom he has co-authored multiple publications.
Metrics
- h-index: 10
- Publications: 32
- Citations: 677
Selected Publications
-
Is Outpatient Supraglottoplasty Possible? Examination of Perioperative Comorbidities and Outcomes (2024)
-
Deoxycholic Acid for Submental Convexity: A MAUDE Database Analysis (2024)
-
Infantile Hemangioma Treated with Propranolol Readmission Trends, Complications of Therapy, and Cost: A PHIS Database Study (2022)
-
Postoperative and 1‐Year Functional Outcomes After Free Flap Surgery Among Patients 80 Years or Older (2022)
-
Cutaneous hyperpigmentation following bleomycin sclerotherapy for vascular malformations (2021)
-
Hereditary Hemorrhagic Telangiectasia and Aspirin‐Exacerbated Respiratory Disease: A Case Report (2021)
Collaboration Network
Top Collaborators
Terry A. Day
7 shared publications
- Systematic review of neuroendocrine carcinomas of the oropharynx
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 7 shared publications
Keisuke Shirai
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Paul E. O’Brien
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Maria Gisele Matheus
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Kristina Godwin
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Amit J. Sood
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Julie A. Vick
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Daniel Martı́n
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Lynn Vitale‐Cross
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Juan Luis Callejas-Varela
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Zhiyong Wang
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Xingyu Wu
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Olivier Harismendy
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Alfredo Molinolo
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Scott M. Lippman
6 shared publications
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics
Sharon Amole
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Lindsey Herberger
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Soroush Farsi
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Retrospective Studies
Meta-analysis and systematic reviews
L Johnson
University of Arkansas for Medical Sciences
Retrospective Studies
Cancer Treatment and Pharmacology
Surgical Simulation and Training
Donald Bodenner
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Retrospective Studies
Cancer Treatment and Pharmacology
Deanne King
University of Arkansas for Medical Sciences
Head and Neck Cancer Studies
Retrospective Studies
Surgical Simulation and Training